Meiogenix

Meiogenix is an agricultural biotechnology firm focused on enhancing crop development through its proprietary chromosome editing technology. Founded in 2010 by Giacomo Bastianelli and Dr. Alain Nicolas, the company originated as a spin-off from the Institut Curie and INRA-transfert in Paris, France. Dr. Nicolas, a CNRS Research Director at Institut Curie, developed the foundational Spo11-assisted technology that allows for targeted stimulation of natural genetic exchanges.

The company's core technology centers on modulating meiotic recombination, the natural process that creates genetic diversity during plant reproduction. Unlike gene editing techniques like CRISPR that make small DNA changes, Meiogenix's platform enables targeted recombination across chromosomes. This approach allows for the combination of complex traits, the isolation of beneficial characteristics from wild varieties, and the streamlined transfer of gene edits into various commercial germplasms. A key benefit of this method is its potential to significantly shorten plant breeding cycles, reducing them from a typical 6-13 years down to 3-7 years. The resulting plant varieties are not considered GMOs as the process assists a natural cellular mechanism without introducing foreign DNA.

Meiogenix operates with a dual structure: a European unit concentrated on basic research in collaboration with academic partners like CIRAD and the Curie Institute, and a U.S. operation focused on commercial development. In March 2022, the company established its U.S. base at Cornell University's Center for Life Science Ventures incubator to leverage the university's agricultural and research expertise. The company's business model involves strategic partnerships with major agricultural players and research institutions. Notable collaborations include a 2020 agreement with Bayer to advance plant breeding and genome editing technologies and a partnership with Cornell to improve maize. Meiogenix aims to serve the commercial seed market, which is valued at over $50 billion, by providing enhanced breeding capabilities for essential crops such as corn, wheat, rice, and tomatoes.

The company has secured significant funding to advance its research and commercialization efforts. After an initial seed round in 2010, Meiogenix closed a $13 million Series A financing round in December 2021, led by Sofinnova Partners and including investors like Genoa Ventures, Bpifrance, and Casdin Capital. This funding was allocated to support its U.S. expansion and product development. In June 2024, Ricardo Garcia de Alba, a former executive at Corteva Agriscience, was appointed CEO to guide the company's next phase of growth.

Keywords: chromosome editing, plant breeding, meiotic recombination, agricultural biotechnology, genetic diversity, crop improvement, seed market, targeted recombination, sustainable agriculture, crop resilience, agritech, genome editing, maize breeding, non-GMO, Sofinnova Partners, Bayer collaboration, Cornell University, plant genetics, food security, linkage drag removal, complex traits, crop yield, disease resistance, natural biodiversity